PUBLICATION

Homozygous EEF1A2 mutation causes dilated cardiomyopathy, failure to thrive, global developmental delay, epilepsy and early death

Authors
Cao, S., Smith, L.L., Padilla-Lopez, S.R., Guida, B.S., Blume, E., Shi, J., Morton, S.U., Brownstein, C.A., Beggs, A.H., Kruer, M.C., Agrawal, P.B.
ID
ZDB-PUB-170916-10
Date
2017
Source
Human molecular genetics   26: 3545-3552 (Journal)
Registered Authors
Beggs, Alan H., Morton, Sarah
Keywords
none
MeSH Terms
  • Animals
  • Cardiomyopathy, Dilated/genetics*
  • Cardiomyopathy, Dilated/metabolism
  • Developmental Disabilities/genetics
  • Epilepsy/genetics
  • Failure to Thrive/genetics
  • Genomics
  • Homozygote
  • Humans
  • Models, Animal
  • Mutation
  • Mutation, Missense/genetics
  • Peptide Elongation Factor 1/genetics*
  • Peptide Elongation Factor 1/metabolism
  • Protein Isoforms/genetics
  • Saccharomyces cerevisiae/metabolism
  • Zebrafish/genetics
  • Zebrafish/metabolism
PubMed
28911200 Full text @ Hum. Mol. Genet.
Abstract
Eukaryotic elongation factor 1A (EEF1A), is encoded by two distinct isoforms, EEF1A1 and EEF1A2; whereas EEF1A1 is expressed almost ubiquitously, EEF1A2 expression is limited such that it is only detectable in skeletal muscle, heart, brain and spinal cord. Currently, the role of EEF1A2 in normal cardiac development and function is unclear. There have been several reports linking de novo dominant EEF1A2 mutations to neurological issues in humans. We report a pair of siblings carrying a homozygous missense mutation p.P333L in EEF1A2 who exhibited global developmental delay, failure to thrive, dilated cardiomyopathy and epilepsy, ultimately leading to death in early childhood. A third sibling also died of a similar presentation, but DNA was unavailable to confirm the mutation. Functional genomic analysis was performed in S. cerevisiae and zebrafish. In S. cerevisiae, there was no evidence for a dominant-negative effect. Previously identified putative de novo mutations failed to complement yeast strains lacking the EEF1A ortholog showing a major growth defect. In contrast, the introduction of the mutation seen in our family led to a milder growth defect. To evaluate its function in zebrafish, we knocked down eef1a2 expression using translation blocking and splice-site interfering morpholinos. EEF1A2-deficient zebrafish had skeletal muscle weakness, cardiac failure and small heads. Human EEF1A2 wild-type mRNA successfully rescued the morphant phenotype, but mutant RNA did not. Overall, EEF1A2 appears to be critical for normal heart function in humans, and its deficiency results in clinical abnormalities in neurologic function as well as in skeletal and cardiac muscle defects.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping